Souhaitez-vous accéder aux communiqués récents ?

Une étude préclinique chez la souris a évalué le potentiel de la technologie nanoprimer à surmonter les barrières courantes rencontrées par les thérapies délivrées par nanoparticules lipidiques (« LNP...

Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with...

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in...

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...

MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical...

- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en los...

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...